ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

BL1107

A development code. Also written as “BL1107 Low dose” and “BL1107 High dose”.

Its studies are mostly in Dry Eye Syndromes · Glaucoma, led by Bausch Health Companies.

Furthest: phase 2, since Sep 5, 20252 company-led studies, 1 open or runningNext primary completion: Feb 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bausch Health Companies21 open or runningphase 2since Sep 5, 2025Sep 5, 2025Feb 2027phase 2 · NCT07778888

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 5, 2025First study: phase 2 study in GlaucomaFirst studyNCT07168902 · 252 enrolled · United States
  2. Aug 18, 2026Phase 2 study in Dry Eye SyndromesNCT07778888 · 20 planned · United States

Ahead

  1. Feb 2027Primary completion: phase 2 study in Dry Eye SyndromesNCT07778888

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07778888Dry Eye Syndromes · United States2RecruitingFeb 202720
NCT07168902Glaucoma · United States2CompletedMay 18, 2026252

How it is read

Names in the registry

  • “BL1107”, 1 entry
  • “BL1107 Low dose”, 1 entry
  • “BL1107 High dose”, 1 entry

Codes read as this program: BL1107.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.